Paromomycin
Based on 4 publication(s) in Google Scholar
Paromomycin (Aminosidine) is an orally active broad-spectrum aminoglycoside aminocyclitol. Paromomycin is produced by Streptomyces riomosus var. Paromomycinus. Paromomycin binding induces local conformational changes in the 16S rRNA A-site. Paromomycin exhibits inhibitory activity against C. parvum. Paromomycin can be used in research related to leishmaniasis, amoebiasis and cryptosporidiosis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 7542-37-2
- 分子式: C23H45N5O14
- 分子量:615.63
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Paromomycin
MoreParasite アイソフォーム固有の製品をすべて表示
MoreEndogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
|
Microbial Metabolite |
Leishmania |
Amebae |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-8 | IC50 |
711 nM
Compound: Paromomycin
|
Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells after 48 hrs by ELISA
Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells after 48 hrs by ELISA
|
[PMID: 18591280] |
| J774.A1 | CC50 |
53.33 μg/mL
Compound: Paromomycin
|
Cytotoxicity against mouse J774A1 cells by MTT assay
Cytotoxicity against mouse J774A1 cells by MTT assay
|
[PMID: 21295472] |
| Peritoneal macrophage cell | IC50 |
>100 μM
Compound: paromomycin
|
Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay
Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay
|
[PMID: 22989363] |
| RAW264.7 | IC50 |
>100 μM
Compound: paromomycin
|
Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay
Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay
|
[PMID: 22989363] |
| Vero | CC50 |
53.3 μM
Compound: Paromomycin
|
Cytotoxicity against african green monkey vero cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against african green monkey vero cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23673014] |
| Vero C1008 | IC50 |
>2.0 × 105M
Compound: COVC-0676336451
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
10.6019/CHEMBL4651402 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6N (female, 6 weeks old, 14-16 g, immunosuppressed with dexamethasone phosphate, infected with Cryptosporidium parvum)[3]
-
Dosage:0.25 g/kg/day; 0.5 g/kg/day; 1 g/kg/day; 2 g/kg/day
-
Administration:p.o.; once daily; 10 consecutive days
-
Result:Significantly reduced fecal oocyst shedding (P < 0.01) at 1 g/kg/day and 2 g/kg/day, with no rebound after initial reduction.
Significantly lowered parasite colonization in ilea (0.02 ± 0.02 C.
parvum/epithelial cell at 1 g/kg/day; 0 C.
parvum/epithelial cell at 2 g/kg/day) and terminal ilea (0.15 ± 0.08 C.
parvum/epithelial cell at 1 g/kg/day; 0.03 ± 0.03 C.
parvum/epithelial cell at 2 g/kg/day) compared to placebo controls (P < 0.05).
Increased villus-to-crypt (V/C) ratios in ilea (1.99 ± 0.08 at 1 g/kg/day; 1.98 ± 0.02 at 2 g/kg/day) and terminal ilea (1.81 ± 0.11 at 1 g/kg/day; 1.91 ± 0.07 at 2 g/kg/day) compared to placebo controls (P < 0.05), indicating reduced villus atrophy.
Reduced oocyst shedding within 24 hours at 0.25 g/kg/day and 0.5 g/kg/day, but rebound occurred starting on day 14 post-infection with shedding exceeding pretreatment levels.
Showed no significant therapeutic benefit for parasite colonization or villus atrophy relative to placebo controls at 0.25 g/kg/day and 0.5 g/kg/day.
化学情報
-
CAS 番号 7542-37-2
-
分子量 615.63
-
分子式 C23H45N5O14
-
SMILES
O[C@H]([C@@H]([C@H](O1)CO)O[C@H]2O[C@H]([C@H]([C@@H]([C@H]2N)O)O)CN)[C@@H]1O[C@H]([C@H]([C@@H](C[C@@H]3N)N)O)[C@@H]3O[C@H]4O[C@@H]([C@H]([C@@H]([C@H]4N)O)O)CO
-
別名
Aminosidine
-
Structure Classification
-
Initial Source
Streptomyces sp
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
Discovery of TRPV4-Targeting Small Molecules with Anti-Influenza Effects Through Machine Learning and Experimental Validation. [Abstract]2025 Feb 6;26(3):1381. PMID: 39941149 -
Comput Biol Chem
Targeting quorum sensing in Pseudomonas aeruginosa with high-affinity inhibitors: A high-throughput screening and in-silico analysis. [Abstract]2025 Aug:117:108419. PMID: 40088808 -
Acta Trop
Paromomycin-loaded mannosylated chitosan nanoparticles: Synthesis, characterization and targeted drug delivery against leishmaniasis. [Abstract]2019 Sep:197:105045. PMID: 31158341 -
Vet Res Commun
Biological characterization of lipoic acid- and heme-dependent Escherichia coli small colony variants isolated from sheep in Xinjiang, China. [Abstract]2024 Dec;48(6):3859-3872. PMID: 39325108
純度とドキュメンテーション
参考文献
[1]. Sundar S, et al. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs. 2008;17(5):787-794. [Content Brief]
[2]. Fourmy D, et al. Paromomycin binding induces a local conformational change in the A-site of 16 S rRNA. J Mol Biol. 1998;277(2):333-345. [Content Brief]
[3]. Healey MC, et al. Therapeutic efficacy of paromomycin in immunosuppressed adult mice infected with Cryptosporidium parvum. J Parasitol. 1995;81(1):114-116. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Powered by Bioz